Literature DB >> 1495578

HLA determinants in familial multiple sclerosis.

M G Grasso1, F Cutrupi, S Bernardi, S Trabace, C Pozzilli, S Cappellacci, C Fieschi.   

Abstract

HLA-A, -B, -C, -DR, -DQ antigens were studied in 11 multiplex MS families, 11 single-case MS families and 100 healthy subjects. The HLA DR4 was the most frequent antigen in all MS patients (p = 0.015). When the antigenic frequency in index familial cases was compared with that in single cases, the DR4 antigen was found to be more frequent (p = 0.01) in familial cases only. Furthermore, when the DR4 antigen was excluded from the analysis, we observed an increase in DR2 (p = 0.11) only in the familial MS cases. These results can be compatible with a multifactorial hypothesis according to which the HLA genes have an important role in MS susceptibility in familial cases.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1495578     DOI: 10.1159/000110916

Source DB:  PubMed          Journal:  Neuroepidemiology        ISSN: 0251-5350            Impact factor:   3.282


  3 in total

1.  Immunodominance of a low-affinity major histocompatibility complex-binding myelin basic protein epitope (residues 111-129) in HLA-DR4 (B1*0401) subjects is associated with a restricted T cell receptor repertoire.

Authors:  P A Muraro; M Vergelli; M Kalbus; D E Banks; J W Nagle; L R Tranquill; G T Nepom; W E Biddison; H F McFarland; R Martin
Journal:  J Clin Invest       Date:  1997-07-15       Impact factor: 14.808

2.  HSP70-1 promoter region polymorphism tested in three autoimmune diseases.

Authors:  I Cascino; M Galeazzi; M Salvetti; G Ristori; G Morozzi; P M Richiardi; R Tosi
Journal:  Immunogenetics       Date:  1994       Impact factor: 2.846

3.  Unique clinical and pathological features in HLA-DRB1*0401-restricted MBP 111-129-specific humanized TCR transgenic mice.

Authors:  Jacqueline A Quandt; Mirza Baig; Karen Yao; Kazuyuki Kawamura; Jaebong Huh; Samuel K Ludwin; Hong-Jin Bian; Mark Bryant; Laura Quigley; Zoltan A Nagy; Henry F McFarland; Paolo A Muraro; Roland Martin; Kouichi Ito
Journal:  J Exp Med       Date:  2004-07-19       Impact factor: 14.307

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.